Dual Therapeutics Announces Oncology Strategic Collaboration with Bristol-Myers Squibb
January 8, 2016 – Dual Therapeutics, LLC (“Dual Therapeutics”) today announced a strategic collaboration with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds for the treatment of cancer and other diseases. Dual Therapeutics’ small-molecule modulators simultaneously block multiple cancer promoting pathways, …
“Dark Matter” in Cancer Genome Prompts Immune Response
December 7, 2015 – Researchers at the Icahn School of Medicine at Mount Sinai have discovered a group of non-coding RNA molecules in cancer cells that sets off an immune response because they appear to have features similar to those of pathogens. As …
Mount Sinai Innovation Partners Launches New Web Resources for Faculty
Mount Sinai Innovation Partners, MSIP, is a business unit of the health system that facilitates the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships. MSIP recently launched new resources on their website, www.ip.mountsinai.org, for faculty, staff and …
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
November 10, 2015 – Boehringer Ingelheim today announced new collaborations with four major scientific partners to enrich research and development of novel therapeutic approaches for patients with inflammatory bowel disease (IBD), including the Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, …
‘JEDI’ Technology Awakens New Understanding of How Immune System Works
November 4, 2015 – When it comes to fending off disease and helping prevent people from falling ill, the body’s immune system — armed with T-cells that help eliminate cancer cells, virus-infected cells and more — is second to none. But exactly how …
Mount Sinai Innovation Awards
On Monday, October 26, 2015, Mount Sinai Innovation Partners sponsored the first ever Mount Sinai Innovation Awards Ceremony, celebrating five new honors that recognize significant contributions in biomedical education and industry. Through the dedication of presenters, participants, attendees, and our generous sponsors, SINAInnovations …
Celmatix Launches Personalized Reproductive Medicine (PReM) Initiative to Decode Fertility Potential
October 19, 2015 – Celmatix, a personalized medicine company focused on fertility and women’s health, today announced the launch of the Personalized Reproductive Medicine (PReM) Initiative, an alliance created to investigate what an individual’s genetic signature and personalized metrics say about his or …
SERCA2a TREATMENT FOR PULMONARY HYPERTENSION
Pulmonary arterial hypertension (PAH) commonly results from heart failure in the left side of the heart or from a pulmonary embolism, when a blood clot in the leg travels to the lungs and cause blockages. When the lung is damaged from these …
Regeneron and Icahn School of Medicine at Mount Sinai Announce New Antibody Research Agreement
September 24, 2015 – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and The Experimental Therapeutics Institute (ETI) at the Icahn School of Medicine at Mount Sinai today announced that they have entered into an agreement with the goal of accelerating the discovery of fully …
GENE-SIGNATURE FOR DIAGNOSIS OF EARLY HEPATOCELLULAR CARCINOMA
The incidence of hepatocellular carcinoma (HCC) is 750,000 new cases globally, it is the second leading cause of cancer-related death and represents a major health problem. When identified at early stages, curative treatments such as resection, transplantation and percutaneous ablation are feasible. …